BET inhibitors are effective for the treatment of hematopoietic cancer, but neuroblastoma cell lines are also among the cell lines that are the most sensitive to BET inhibition [77]. This evidence concerns the gene DNER and hematopoietic and lymphoid cell neoplasm.